Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2016;2016:580–8.

Article  Google Scholar 

Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2014;6:e2014073.

Article  PubMed  PubMed Central  Google Scholar 

Westbrook CA. Molecular subsets and prognostic factors in acute lymphoblastic leukemia. Leukemia 1997;11:S8–10.

PubMed  Google Scholar 

Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia - PubMed [Internet]. [cited 2023 May 27]. Available from: https://pubmed.ncbi.nlm.nih.gov/28821272/

Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, Lambert J, Beldjord K, Lengliné E, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol J Am Soc Clin Oncol. 2013;31:4333–42.

Article  CAS  Google Scholar 

Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, et al. Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:2683–91.

Article  CAS  Google Scholar 

Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia 2021;35:3044–58.

Article  PubMed  Google Scholar 

Socié G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, et al. Long- term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341:14–21.

Article  PubMed  Google Scholar 

Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2020;188:745–56.

Article  CAS  PubMed  Google Scholar 

El-Cheikh J, El Dika I, Massoud R, Charafeddine M, Mahfouz R, Kharfan-Dabaja MA, et al. Hyper-CVAD compared with BFM-like chemotherapy for the treatment of adult acute lymphoblastic leukemia. a retrospective single-center analysis. Clin Lymphoma Myeloma Leuk. 2017;17:179–85.

Article  PubMed  Google Scholar 

Uzunel M, Mattsson J, Jaksch M, Remberger M, Ringdén O. The significance of graft- versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood. 2001;98:1982–4.

Article  CAS  PubMed  Google Scholar 

Champlin R, Gale RP. Acute lymphoblastic leukemia: recent advances in biology and therapy. Blood. 1989;73:2051–66.

Article  CAS  PubMed  Google Scholar 

Lee S, Kim D-W, Cho B, Kim Y-J, Kim Y-L, Hwang J-Y, et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse- transcription polymerase chain reaction. Br J Haematol. 2003;120:145–53.

Article  CAS  PubMed  Google Scholar 

Hefazi M, Litzow MR. Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia. Blood Lymphat Cancer Targets Ther. 2018;8:47–61.

Article  CAS  Google Scholar 

Fracchiolla NS, Sciumè M, Papayannidis C, Vitale A, Chiaretti S, Annunziata M, et al. Blinatumomab and inotuzumab ozogamicin sequential use for the treatment of relapsed/refractory acute lymphoblastic leukemia: a real-life campus all study. Cancers. 2023;15:4623.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malczewska M, Kośmider K, Bednarz K, Ostapińska K, Lejman M, Zawitkowska J. Recent advances in treatment options for childhood acute lymphoblastic leukemia. Cancers 2022;14:2021.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leong S, Inglott S, Papaleonidopoulou F, Orfinada K, Ancliff P, Bartram J, et al. CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy. Blood Adv. 2020;4:4665–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun W, Huang X. Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy. Chin Med J (Engl). 2022;135:890–900.

Article  CAS  PubMed  Google Scholar 

Corvò R, Lamparelli T, Bruno B, Barra S, Van Lint MT, Vitale V, et al. Low-dose fractionated total body irradiation (TBI) adversely affects prognosis of patients with leukemia receiving an HLA-matched allogeneic bone marrow transplant from an unrelated donor (UD- BMT). Bone Marrow Transpl. 2002;30:717–23.

Article  Google Scholar 

Giebel S, Miszczyk L, Slosarek K, Moukhtari L, Ciceri F, Esteve J, et al. Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2014;120:2760–5.

Article  PubMed  Google Scholar 

Belkacemi Y, Labopin M, Giebel S, Loganadane G, Miszczyk L, Michallet M, et al. Single-dose daily fractionation is not inferior to twice-a-day fractionated total-body irradiation before allogeneic stem cell transplantation for acute leukemia: a useful practice simplification resulting from the SARASIN study. Int J Radiat Oncol Biol Phys. 2018;102:515–26.

Article  PubMed  Google Scholar 

Gao RW, Weisdorf DJ, DeFor TE, Ehler E, Dusenbery KE. Influence of total body irradiation dose rate on idiopathic pneumonia syndrome in acute leukemia patients undergoing allogeneic hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2019;103:180–9.

Article  PubMed  Google Scholar 

Nagler A, Dholaria B, Labopin M, Savani BN, Angelucci E, Koc Y, et al. Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. Leukemia. 2020;34:2766–75.

Article  CAS  PubMed  Google Scholar 

Baron F, Mohty M, Blaise D, Socié G, Labopin M, Esteve J, et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:224–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li S-Q, Fan Q-Z, Xu L-P, Wang Y, Zhang X-H, Chen H, et al. Different effects of pre- transplantation measurable residual disease on outcomes according to transplant modality in patients with philadelphia chromosome positive ALL. Front Oncol. 2020;10:320.

Article  PubMed  PubMed Central  Google Scholar 

Giebel S, Labopin M, Czerw T, Socié G, Blaise D, Ghavamzadeh A, et al. Impact of anti- thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: an analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer. 2019;106:212–9.

Article  CAS  PubMed  Google Scholar 

Czerw T, Labopin M, Giebel S, Socié G, Volin L, Fegueux N, et al. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT. Cancer. 2018;124:2523–33.

Article  CAS  PubMed  Google Scholar 

Giebel S, Labopin M, Socié G, Beelen D, Browne P, Volin L, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:139–49.

Article  PubMed  PubMed Central  Google Scholar